M. Hofmann, O. Stoss, D. Shi, R. Büttner, M. V. Vijver, Woosuk Kim, A. Ochiai, J. Rüschoff, T. Henkel
2008.6.1HISTOPATHOLOGY
tlooto Summary
The aim was to establish a HER2 scoring system for gastric cancer to identify suitable patients for enrolment in a trial of trastuzumab (Herceptin®) in advanced metastatic Gastric cancer.
Abstract
Aims: Human epidermal growth factor receptor 2 (HER2) overexpression/amplification is implicated in the development of various solid tumour types. Validated methods and scoring systems for evaluating HER2 status exist in breast cancer, but not in gastric cancer. The aim was to establish a HER2 scoring system for gastric cancer to identify suitable patients for enrolment in a trial of trastuzumab (Herceptin®) in advanced metastatic gastric cancer.
Citation format
HOFMANN, M., et al. Assessment of a HER2 scoring system for gastric cancer: Results from a validation study. HISTOPATHOLOGY, 2008, 52.